{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:18:08Z","timestamp":1790687888079,"version":"4.1.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>SARS-CoV-2 transmission mainly occurs through exposure of the upper airway mucosa to infected secretions such as saliva, which are excreted by an infected person. Thus, oral mucosal immunity plays a central role in the prevention of and early defense against SARS-CoV-2 infection. Although virus-specific antibody response has been extensively investigated in blood samples of SARS-CoV-2-infected patients and vaccinees, local humoral immunity in the oral cavity and its relationship to systemic antibody levels needs to be further addressed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>We fine-tuned a virus neutralization assay (vNTA) to measure the neutralizing activity (NA) of plasma and saliva samples from 20 SARS-CoV-2-infected (SI), 40 SARS-CoV-2-vaccinated (SV), and 28 SARS-CoV-2-vaccinated subjects with a history of infection (SIV) using the \u201cwild type\u201d SARS-CoV-2 lineage B.1 (EU) and the Delta (B.1.617.2) strains. To validate the vNTA results, the presence of neutralizing antibodies (NAbs) to the spike receptor binding domain (RBD) was evaluated with an ELISA assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>NA to SARS-CoV-2 lineage B.1 (EU) was present in plasma samples from all the tested subjects, with higher titers in SIV compared to both SI and SV. Conversely, NA was detected in saliva samples from 10.3% SV, 45% SI, and 92.6% SIV, with significantly lower titers in SV compared to both SI and SIV. The detection of NAbs in saliva reflected its reduced NA in SV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The difference in NA of plasma vs. saliva was confirmed in a vNTA where the SARS-CoV-2 B.1 and Delta strains were tested head-to-head, which also revealed a reduced NA of both specimens compared to the B.1 variant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The administration of SARS-CoV-2 vaccines was associated with limited virus NA in the oral cavity, as measured in saliva and in comparison to plasma. This difference was more evident in vaccinees without a history of SARS-CoV-2 infection, possibly highlighting the importance of local exposure at the site of virus acquisition to effectively prevent the infection and block its spread. Nevertheless, the presence of immune escape mutations as possibly represented by the SARS-CoV-2 Delta variant negatively affects both local and systemic efficacy of NA associated with vaccination.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.820250","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T06:28:16Z","timestamp":1646980096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees"],"prefix":"10.3389","volume":"13","author":[{"given":"Micaela","family":"Garziano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Utyro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Poliseno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Antonia","family":"Santantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Saulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Strizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Introini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Biasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","article-title":"Molecular Interaction and Inhibition of SARS-CoV-2 Binding to the ACE2 Receptor","volume":"11","author":"Yang","year":"2020","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus From Patients With Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009637117","article-title":"Identifying Airborne Transmission as the Dominant Route for the Spread of COVID-19","volume":"117","author":"Zhang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02204-20","article-title":"COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva","volume":"59","author":"Pisanic","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B5","unstructured":"A Mucosal Antibody Response is Induced by Intra-Muscular SARS-CoV-2 mRNA VaccinationMedrxiv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v6i1.441","article-title":"Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva","volume":"6","author":"Ketas","year":"2021","journal-title":"Pathog Immun"},{"key":"B7","unstructured":"Intramuscular SARS-CoV-2 Vaccines Elicit Varying Degrees of Plasma and Salivary Antibody Responses as Compared to Natural InfectionMedrxiv"},{"key":"B8","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41591-021-01296-8","article-title":"SARS-CoV-2 Infection of the Oral Cavity and Saliva","volume":"27","author":"Huang","year":"2021","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006798","article-title":"Initial Acquisition and Succession of the Cystic Fibrosis Lung Microbiome is Associated With Disease Progression in Infants and Preschool Children","volume":"14","author":"Muhlebach","year":"2018","journal-title":"PloS Pathog"},{"key":"B10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2020.05.048","article-title":"The Intermucosal Connection Between the Mouth and Gut in Commensal Pathobiont-Driven Colitis","volume":"182","author":"Kitamoto","year":"2020","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.08.005","article-title":"Tissue-Specific Immunity at the Oral Mucosal Barrier","volume":"39","author":"Moutsopoulos","year":"2018","journal-title":"Trends Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dmrr.2916","article-title":"Marker of Coxsackievirus-B4 Infection in Saliva of Patients With Type 1 Diabetes","volume":"33","author":"Badia-Boungou","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05128-11","article-title":"Neutralizing Activity of Saliva Against Cytomegalovirus","volume":"18","author":"Saccoccio","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax Augments B and T Cell Responses Upon Influenza Vaccination via the Respiratory Tract and Enables Complete Protection of Mice Against Lethal Influenza Virus Challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J Control Release"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/v13040655","article-title":"SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus","volume":"13","author":"Matusali","year":"2021","journal-title":"Viruses"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4388","article-title":"Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination","volume":"325","author":"Edara","year":"2021","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/mps4010007","article-title":"Inactivation of Material From SARS-CoV-2-Infected Primary Airway Epithelial Cell Cultures","volume":"4","author":"Barrow","year":"2021","journal-title":"Methods Protoc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753435","article-title":"Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children","volume":"12","author":"Heinzel","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 Transmission and Pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251342","article-title":"Development and Validation of a Quantitative, non-Invasive, Highly Sensitive and Specific, Electrochemical Assay for Anti-SARS-CoV-2 IgG Antibodies in Saliva","volume":"16","author":"Chiang","year":"2021","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab256","article-title":"Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys","volume":"224","author":"Alkharaan","year":"2021","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody Responses in Seropositive Persons After a Single Dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2004866","article-title":"SARS-CoV-2 mRNA Vaccine BNT162b2 Triggers a Consistent Cross-Variant Humoral and Cellular Response","volume":"10","author":"Mileto","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.798859","article-title":"SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination","volume":"12","author":"Pinilla","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal Immune Response in BNT162b2 COVID-19 Vaccine Recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"eBioMedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-3611-1.50065-9","article-title":"Alternative Vaccine Delivery Methods","author":"Weniger","year":"2008","journal-title":"Vaccines"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01605","article-title":"Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections","volume":"10","author":"Calzas","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030341","article-title":"Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines","volume":"8","author":"Folorunso","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008521.pub5","article-title":"Vaccines for Preventing Rotavirus Diarrhoea: Vaccines in Use","volume":"2019","author":"Soares-Weiser","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0518","article-title":"The \u201cPerformance of Rotavirus and Oral Polio Vaccines in Developing Countries\u201d (PROVIDE) Study: Description of Methods of an Interventional Study Designed to Explore Complex Biologic Problems","volume":"92","author":"Kirkpatrick","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001261.pub4","article-title":"Vaccines for Preventing Typhoid Fever","volume":"2018","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100354","article-title":"Longitudinal Analysis Shows Durable and Broad Immune Memory After SARS-CoV-2 Infection With Persisting Antibody Responses and Memory B and T Cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00974-0","article-title":"Neutralizing Antibody Activity in Convalescent Sera From Infection in Humans With SARS-CoV-2 and Variants of Concern","volume":"6","author":"Dupont","year":"2021","journal-title":"Nat Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of Antibody Immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"B36","unstructured":"The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) VaccinesImmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952","article-title":"A Neutralizing Human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1038\/s41598-021-85202-9","article-title":"SARS-CoV-2-Induced Humoral Immunity Through B Cell Epitope Analysis in COVID-19 Infected Individuals","volume":"11","author":"Yoshida","year":"2021","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-Terminal Domain Antigenic Mapping Reveals a Site of Vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and Protective Human Monoclonal Antibodies Recognizing the N-Terminal Domain of the SARS-CoV-2 Spike Protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00068-9","article-title":"SARS-CoV-2 Spike E484K Mutation Reduces Antibody Neutralisation","volume":"2","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"key":"B43","unstructured":"The Effect of Spike Mutations on SARS-CoV-2 NeutralizationCrick"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61312","article-title":"Escape From Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"eLife"},{"key":"B45","unstructured":"Neutralization of SARS-CoV-2 Spike 69\/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited SeraNature Medicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1940305","article-title":"Serosurvey in BNT162b2 Vaccine-Elicited Neutralizing Antibodies Against Authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 Variants","volume":"10","author":"Zani","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","article-title":"A Single Dose of the SARS-CoV-2 Vaccine BNT162b2 Elicits Fc-Mediated Antibody Effector Functions and T Cell Responses","volume":"29","author":"Tauzin","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759688","article-title":"Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals","volume":"12","author":"Klingler","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401771","article-title":"Protective Efficacy of Individual CD8+ T Cell Specificities in Chronic Viral Infection","volume":"194","author":"Johnson","year":"2015","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.820250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T06:28:22Z","timestamp":1646980102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.820250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.820250"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.820250","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"article-number":"820250"}}